XW0433A
Introduction of Bentracimab, Ticagrelor Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 10
- Release
- FY 2027
- Effective
Character Breakdown
Each character position in XW0433A resolves to one value from the official ICD-10-PCS tables.
- 1. Section X — New Technology
- 2. Body System W — Anatomical Regions
- 3. Operation 0 — Introduction
- 4. Body Part 4 — Central Vein
- 5. Approach 3 — Percutaneous
- 6. Device / Substance / Technology 3 — Bentracimab, Ticagrelor Reversal Agent
- 7. Qualifier A — New Technology Group 10
- 0 · Operation: Introduction
- Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
Hierarchy
Where XW0433A sits in the official hierarchy. Each level is the code it is classified under.
- XW0 Parent New Technology, Anatomical Regions, Introduction
- XW0433A This code Introduction of Bentracimab, Ticagrelor Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 10
Version History
How XW0433A appears in each release imported from the official files, newest first.
-
FY 2027 Effective
CurrentIntroduction of Bentracimab, Ticagrelor Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 10
-
FY 2026 Effective
UnchangedIntroduction of Bentracimab, Ticagrelor Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 10
Related Codes
Other codes under XW0
- XW01318 Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8 Billable
- XW01329 Introduction of Talquetamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9 Billable
- XW01348 Introduction of Teclistamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8 Billable
- XW0134C Introduction of Elamipretide into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 12 Billable
- XW0136A Introduction of Dasiglucagon into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 10 Billable
- XW013F5 Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5 Billable
- XW013G6 Introduction of REGN-COV2 Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 Billable
- XW013H6 Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 Billable
- XW013K6 Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 Billable
- XW013L9 Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9 Billable
- XW013S6 Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 Billable
- XW013S9 Introduction of Epcoritamab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9 Billable
- XW013T6 Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 Billable
- XW013TB Introduction of Rozanolixizumab-noli Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 11 Billable
- XW013U6 Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 Billable
- XW013V7 Introduction of COVID-19 Vaccine Dose 3 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7 Billable
- XW013W5 Introduction of Caplacizumab into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5 Billable
- XW013W7 Introduction of COVID-19 Vaccine Booster into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7 Billable
- XW020D8 Introduction of Engineered Allogeneic Thymus Tissue into Muscle, Open Approach, New Technology Group 8 Billable
- XW023S6 Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous Approach, New Technology Group 6 Billable
- XW023T6 Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous Approach, New Technology Group 6 Billable
- XW023U6 Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New Technology Group 6 Billable
- XW023V7 Introduction of COVID-19 Vaccine Dose 3 into Muscle, Percutaneous Approach, New Technology Group 7 Billable
- XW023W7 Introduction of COVID-19 Vaccine Booster into Muscle, Percutaneous Approach, New Technology Group 7 Billable
Data Source
Code information on this page is derived from the FY 2027 ICD-10-PCS files published by CMS.
- Release
- FY 2027
- Effective
- Source file
- 2027-icd-10-pcs-order-file-long-abbreviated-titles.zip
Official ICD-10-PCS source files (opens in a new tab)
MedCodeSearch is an independent reference service and is not affiliated with CMS, CDC, or the U.S. government.
Look up another code
Search ICD-10-CM, ICD-10-PCS and HCPCS Level II by code or description.